Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:27 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies
NCT02629692 · Sun Pharma Advanced Research Company Limited · PHASE1/PHASE2 · terminated · last registry update 2026-05-13 · Chronic myeloid leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Closed for administrative, non-safety-related reasons.” | Open Targets' class: business administrative | Registry record, Sun Pharma Advanced Research Company Limited |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ABL1 in chronic myeloid leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-29Phase 3 first posted: Enliven Therapeutics, ELVN-001 + TKI (NCT07905183)
- 2026-10-29Results posted on the registry: Novartis Pharmaceuticals, imatinib mesylate (NCT01742299)
- 2026-10-21Phase 3 first posted: Jiangsu Hansoh Pharmaceutical Co., Ltd., HS-10382 + Imatinib (NCT07885293)
- 2026-07-13Also stopped (terminated): Novartis Pharmaceuticals, Nilotinib + Nilotinib (NCT03874858)
- 2026-05-29Also stopped (terminated): Sarit Assouline, Asciminib + Imatinib (NCT05413915)
- 2026-05-27Results posted on the registry: Novartis Pharmaceuticals, Asciminib + Nilotinib (NCT05456191)
- 2026-03-02Also stopped (terminated): M.D. Anderson Cancer Center, Asciminib (NCT04216563)
- 2026-01-15Results posted on the registry: M.D. Anderson Cancer Center, Dasatinib (NCT00254423)
- 2026-01-09Results posted on the registry: M.D. Anderson Cancer Center, Asciminib (NCT04216563)
- 2025-12-18Results posted on the registry: SWOG Cancer Research Network, Bosutinib + Dasatinib (NCT03654768)
- 2025-06-03Also stopped (terminated): M.D. Anderson Cancer Center, Dasatinib + Imatinib Mesylate (NCT01751425)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision